Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

VX-702

Catalog No. T2513Cas No. 745833-23-2
Alias 479543-46-9

VX-702 is a highly specific p38α MAPK inhibitor, 14-fold higher selectivity for the p38α than p38β. VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA).

VX-702

VX-702

Purity: 100%
Catalog No. T2513Alias 479543-46-9Cas No. 745833-23-2
VX-702 is a highly specific p38α MAPK inhibitor, 14-fold higher selectivity for the p38α than p38β. VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA).
Pack SizePriceAvailabilityQuantity
10 mg$50In Stock
25 mg$77In Stock
50 mg$135In Stock
1 mL x 10 mM (in DMSO)$50In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "VX-702"

Select Batch
Purity:100%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
VX-702 is a highly specific p38α MAPK inhibitor, 14-fold higher selectivity for the p38α than p38β. VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA).
Targets&IC50
p38α:4 nM-20 nM
In vitro
Administering VX-702 (0.1 mg/kg) twice daily exhibited effects similar to those of methotrexate (0.1 mg/kg). Furthermore, the efficacy of administering VX-702 (5 mg/kg) twice daily was akin to that of a once-daily dose of prednisolone (10 mg/kg). The MI/AAR ratio in the group treated with VX-702 (50 mg/kg) was significantly lower compared to both the control group and the group treated with VX-702 at 5 mg/kg. VX-702 has a half-life of 16-20 hours, a clearance volume of 3.75 L, and a distribution volume of 73 L/kg. It selectively inhibits the activity of p38 MAPK without affecting ERKs and JNKs.
In vivo
VX-702 does not inhibit platelet aggregation induced by p38 MAPK activators. Treatment with VX-702 (1 μM) can completely or partially suppress p38 activity induced by various platelet activators, including thrombin, AYPGKF, SFLLRN, U46619, and collagen, with an IC50 ranging from 4-20 nM. Additionally, VX-702 dose-dependently inhibits the production of IL-6 (IC50: 59 ng/ml), IL-1β (IC50: 122 ng/ml), and TNFα (IC50: 99 ng/ml).
Kinase Assay
HDAC enzyme assay in vitro: The deacetylase enzyme assay is based on a homogeneous fluorescence release assay. Purified recombinant HDAC enzymes are incubated with MGCD0103 diluted in various concentrations for 10 minutes in assay buffer [25 mM HEPES (pH 8.0), 137 mM NaCl, 1 mM MgCl2, 2.7 mM KCl] at room temperature. The substrate Boc-Lys(ε-Ac)-AMC is added to the reaction for further incubation at 37 °C. The concentration of the substrate and the incubation time varies for different isotypes of HDAC enzymes. A 20-min trypsin incubation at room temperature allows the release of the fluorophore from the deacetylated substrate. The fluorescent signal is detected by fluorometer at excitation of 360 nm, emission of 470 nm, and cutoff at 435 nm.
Alias479543-46-9
Chemical Properties
Molecular Weight404.32
FormulaC19H12F4N4O2
Cas No.745833-23-2
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 60 mg/mL (148.4 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.4733 mL12.3664 mL24.7329 mL123.6644 mL
5 mM0.4947 mL2.4733 mL4.9466 mL24.7329 mL
10 mM0.2473 mL1.2366 mL2.4733 mL12.3664 mL
20 mM0.1237 mL0.6183 mL1.2366 mL6.1832 mL
50 mM0.0495 mL0.2473 mL0.4947 mL2.4733 mL
100 mM0.0247 mL0.1237 mL0.2473 mL1.2366 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy VX-702 | purchase VX-702 | VX-702 cost | order VX-702 | VX-702 chemical structure | VX-702 in vivo | VX-702 in vitro | VX-702 formula | VX-702 molecular weight